Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease

G De Rubis, KR Paudel, L Corrie, S Mehndiratta… - Naunyn-Schmiedeberg's …, 2024 - Springer
Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) are among the
leading causes of mortality worldwide. Cigarette smoking is among the main aetiologic …

Prevention of acute exacerbations of COPD: American college of chest physicians and Canadian thoracic society guideline

GJ Criner, J Bourbeau, RL Diekemper, DR Ouellette… - Chest, 2015 - Elsevier
BACKGROUND: COPD is a major cause of morbidity and mortality in the United States as
well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of …

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study

NR Anthonisen, JE Connett, JP Kiley, MD Altose… - Jama, 1994 - jamanetwork.com
Objective.—To determine whether a program incorporating smoking intervention and use of
an inhaled bronchodilator can slow the rate of decline in forced expiratory volume in 1 …

Hospitalizations and mortality in the Lung Health Study

NR Anthonisen, JE Connett, PL Enright… - American journal of …, 2002 - atsjournals.org
This report deals with deaths and hospitalizations during the 5-year Lung Health Study, as
documented by examination of appropriate records. There were 149 deaths (2.5%) during …

The problems of anticholinergic adverse effects in older patients

M Feinberg - Drugs & aging, 1993 - Springer
The old saying 'red as a beet, dry as a bone, blind as a bat, hot as a hare, mad as a hatter'is
often quoted when describing the autonomic effects of drugs that block the muscarinic …

Contemporary management of chronic obstructive pulmonary disease: scientific review

DD Sin, FA McAlister, SFP Man, NR Anthonisen - Jama, 2003 - jamanetwork.com
Context The care of patients with chronic obstructive pulmonary disease (COPD) has
changed radically over the past 2 decades, and novel therapies can not only improve the …

Pharmacoeconomic evaluation of COPD

DE Hilleman, N Dewan, M Malesker, M Friedman - Chest, 2000 - Elsevier
Study objectives The clinical outcomes and health-carecosts of a cohort of 413 patients with
COPD are reported. Design This study was a retrospective pharmacoeconomicanalysis …

Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit …

C Vogelmeier, R Buhl, CP Criée, A Gillissen… - …, 2007 - thieme-connect.com
Der folgende Text stellt eine Überarbeitung der Leitlinie der Deutschen Atemwegsliga und
der Deutschen Gesellschaft für Pneumologie von 2002 [1] dar. Diese ist notwendig …

Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians

A Qaseem, V Snow, P Shekelle, K Sherif… - Annals of internal …, 2007 - acpjournals.org
Recommendation 1: In patients with respiratory symptoms, particularly dyspnea, spirometry
should be performed to diagnose airflow obstruction. Spirometry should not be used to …

Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD

BC Moulton, AD Fryer - British journal of pharmacology, 2011 - Wiley Online Library
In the lungs, parasympathetic nerves provide the dominant control of airway smooth muscle
with release of acetylcholine onto M3 muscarinic receptors. Treatment of airway disease …